TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12378667
Drug: Rocuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.1 mg kg‐1
Study: 12378667
Drug: Rocuronium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.15 mg kg‐1
Study: 12378667
Drug: Rocuronium 0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.22 mg kg‐1
Study: 12378667
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg kg‐1
Study: 12378667
Drug: Rocuronium 0.29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.29 mg kg‐1 (ED95)
Study: 10529324
Drug: Streptokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase therapy with r-hirudin or heparin
Study: 2270358
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 50 mg.kg‐1.h‐1
Study: 531232
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (200 mg x 3)
Study: 531232
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg x 3)
Study: 531232
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (0.5 g x 3)
Study: 24052453
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in specialty outpatient addiction treatment program
Study: 22703421
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 μg
Study: 22703421
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin 10 iu
Study: 19224679
Drug: ACTS infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTS infusion intervention
Study: 17805075
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (30 microg of ethinyl estradiol and 0.3 mg of norgestrel) for 2 years
Study: 15356032
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids and carbohydrates supplementation (16.5 g essential amino acids and 30 g carbohydrates at 1100, 1600, and 2100 h)
Study: 12174005
Drug: Ivermectin 200
Normalized name: ivermectin 200 ug / praziquantel 1.5 mg ORAL PASTE [Equimax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 200 micro g/kg orally
Study: 10442367
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 IV infusion on day 1) and UFT (300-600 mg/day orally) plus oral calcium folinate (90 mg/day in three divided doses for 14 days)
Study: 10442367
Drug: UFT (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300-600 mg/day orally) plus oral calcium folinate (90 mg/day in three divided doses for 14 days)
Study: 10442367
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 IV infusion on day 1)
Study: 10442367
Drug: UFT (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (600 mg/day orally)
Study: 7822661
Drug: Budesonide doses
Normalized name: budesonide Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide doses
Study: 708024
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg doxycycline (or 4 mg/kg in patients less than 15 years old)
Study: 708024
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of doxycycline, 500 mg over 4 days (or 10 mg/kg in patients less than 15 years old)
Study: 708024
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg doxycycline (or 4 mg/kg in children)
Study: 28052471
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education computer game
Study: 23416718
Drug: Remifentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (2 ng.ml‐1 target)
Study: 23416718
Drug: Sufentanil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.2 ng.ml‐1 target)
Study: 16923247
Drug: Allopurinol (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (an inhibitor of xanthine oxidase)
Study: 15606222
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 1g and intravenous azithromycin 500 mg daily
Study: 15606222
Drug: Intravenous levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous levofloxacin 500 mg daily
Study: 14752875
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention (five sessions of physical therapy and an individualized home exercise program)
Study: 6786730
Drug: Protective environment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective environment with prophylactic oral nonabsorbable antibiotics
Study: 30886898
Drug: Budesonide combined
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide combined with noninvasive mechanical ventilation (10 days treatment)
Study: 28146658
Drug: Bicalutamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (150 mg daily for 24 months)
Study: 25957224
Drug: Clopidogrel-aspirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin therapy (loading dose of 300 mg of clopidogrel on day 1, followed by 75 mg of clopidogrel per day for 90 days, plus 75 mg of aspirin per day for the first 21 days)
Study: 25957224
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (75 mg/d for 90 days)
Study: 17251510
Drug: Probiotic cheese
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic cheese (50 g daily)
Study: 17251510
Drug: Control cheese
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cheese (50 g daily)
Study: 15823764
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg/ibuprofen 400 mg
Study: 11525072
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise program for eight months, with an intensity of 60% to 80% of heart rate reserve, consisting of three weekly sessions of 60 minutes each.
Study: 22634964
Drug: Acute bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute bicarbonate (0.3 g/kg BM)
Study: 22634964
Drug: Chronic bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic bicarbonate (0.5 g/kg BM daily for 3 days)
Study: 1410168
Drug: Nasal nicotine
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal nicotine spray (2 mg nicotine base, mean 27.8 micrograms/kg)
Study: 1410168
Drug: Nasal nicotine
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal nicotine spray
Study: 1410168
Drug: Nasal nicotine
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal nicotine spray (ad libitum use)
Study: 31305874
Drug: Nabiximols (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (up to 32 sprays daily, containing 86.4 mg tetrahydrocannabinol and 80 mg cannabidiol)
Study: 28899206
Drug: Augmented acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented acupuncture (LI4, LIV3, EX-HN3, GV20, LU7, KID6, including intradermal needles for sustained treatment)
Study: 27418034
Drug: Fortified cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified cereal (50 g) with 150 ml semi-skimmed milk, consumed daily for 12 weeks
Study: 27418034
Drug: Unfortified cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfortified cereal (50 g) with 150 ml semi-skimmed milk, consumed daily for 12 weeks
Study: 27418034
Drug: Fortified cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified cereal (50 g) with 150 ml semi-skimmed milk
Study: 22699751
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg daily for up to 3 months)
Study: 22699751
Drug: Zeaxanthin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zeaxanthin (10 mg daily for up to 3 months)
Study: 2145718
Drug: Subunit plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit plasma vaccine against hepatitis B, administered in three injections.
Study: 28584075
Drug: Sensor augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor augmented pump (SAP) therapy
Study: 9666940
Drug: 0.025 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/day transdermal 17 beta‐estradiol
Study: 9666940
Drug: 0.05 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/day transdermal 17 beta‐estradiol
Study: 9666940
Drug: 0.1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/day transdermal 17 beta‐estradiol
Study: 7867109
Drug: meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 50 mg with diazepam approximately 90 micrograms.kg‐1 (Group D)
Study: 628532
Drug: Insulin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (20 units NPH and 10 units regular) and diabetic diet
Study: 628532
Drug: Neither diet
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither diet nor insulin
Study: 23126214
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac p.o. one hour prior to surgery
Study: 18593060
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (4g)
Study: 10795554
Drug: iopromid (low‐osmolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromid (low‐osmolar non‐ionic contrast agent)
Study: 8667132
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg capsules, 2 taken 30 minutes prior to surgery, redosed prn)
Study: 8667132
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen with hydrocodone (not premedicated, prn regimen)
Study: 1653901
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of morphine intraarticularly and saline intravenously (Group 1)
Study: 1653901
Drug: Saline intraarticularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intraarticularly and 1 mg of morphine intravenously (Group 2)
Study: 1653901
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of morphine intraarticularly and saline intravenously (Group 3)
Study: 1653901
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of morphine and 0.1 mg of naloxone intraarticularly and saline intravenously (Group 4)
Study: 6687805
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with amethocaine 12‐14 mg plus morphine 1 mg (group II)
Study: 6687805
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with amethocaine 12‐14 mg (group I)
Study: 30400726
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of pantoprazole
Study: 30400726
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing with pantoprazole
Study: 26905932
Drug: Task-sharing counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-sharing counselling intervention for maternal depression (details on dosage and duration not available)
Study: 22546716
Drug: Incorporating 60
Normalized name: Liposome-incorporated DTP-GDP
DrugBank: Liposomal N-acetylglucosminyl-N-acetylmuramly-L-Ala-D-isoGln-L-Ala-gylceroldipalmitoyl (DB17316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorporating 60 g/day whole grains into the diet for 16 weeks
Study: 22546716
Drug: Incorporating 60
Normalized name: Liposome-incorporated DTP-GDP
DrugBank: Liposomal N-acetylglucosminyl-N-acetylmuramly-L-Ala-D-isoGln-L-Ala-gylceroldipalmitoyl (DB17316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorporating 60 g/day whole grains into the diet for 8 weeks, doubling to 120 g/day for the following 8 weeks
Study: 20193253
Drug: Aminophylline delivered
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline delivered via remote controlled capsule to the small bowel
Study: 20193253
Drug: Aminophylline delivered
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline delivered via remote controlled capsule to the ascending colon
Study: 18577477
Drug: Urso treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urso treatment
Study: 18577477
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no urso treatment)
Study: 6122100
Drug: GL enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: GL enzyme (hyaluronidase preparation)
Study: 12375683
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg orally every 4 h
Study: 9928780
Drug: Sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5 mg
Study: 31145173
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol 1 to 2 mg/kg pretreatment to deepen anesthesia to BIS<40
Study: 31145173
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - intravenous saline pretreatment before PCTG puncture and anesthesia targeted to BIS 40 to 60
Study: 31145173
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group - intravenous propofol 1 to 2 mg/kg pretreatment
Study: 30286558
Drug: α-Lipoic Acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Lipoic Acid (ALA) 900 mg daily for 10 days
Study: 24352340
Drug: udenafil 100
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil 100 mg/day
Study: 20029053
Drug: Video self-modeling
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video self-modeling (VSM) following speech restructuring treatment
Study: 16280763
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg + Tamoxifen 10 mg
Study: 16280763
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg + Radiotherapy (RT)
Study: 12442242
Drug: Comparison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatment (papain or vinegar)
Study: 12442242
Drug: Hot-water immersion
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot-water immersion vs Comparison treatment
Study: 10624639
Drug: Fentanyl 100
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 100 micrograms loading dose and 70 micrograms.h‐1 continuous infusion
Study: 10624639
Drug: Fentanyl 200
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 200 micrograms loading dose and 150 micrograms.h‐1 continuous infusion
Study: 1974686
Drug: formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol (12 micrograms inhalation b.i.d.)
Study: 1974686
Drug: salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (200 micrograms inhalation q.i.d.)
Study: 7426230
Drug: Hyperbaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric solution (10 mg amethocaine)
Study: 7426230
Drug: Hyperbaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric solution (15 mg amethocaine)
Study: 7426230
Drug: Isobaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric solution (10 mg amethocaine)
Study: 7426230
Drug: Isobaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric solution (15 mg amethocaine)
Study: 7426230
Drug: Hypobaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric solution (10 mg amethocaine)
Study: 7426230
Drug: Hypobaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric solution (15 mg amethocaine)
Study: 7426230
Drug: Amethocaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine 15 mg
Study: 7426230
Drug: Amethocaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine 10 mg
Study: 24678066
Drug: Muscle patch
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle patch
Study: 18502162
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human arylsulfatase B (rhASB) at 1 mg/kg weekly infusions
Study: 15895275
Drug: Subcutaneous IFNbeta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFNbeta‐1b (Betaferon) treatment
Study: 12233808
Drug: Ginger syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger syrup (1 tablespoon in 4 to 8 ounces of hot or cold water, 4 times daily)
Study: 12233808
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (1 tablespoon in 4 to 8 ounces of hot or cold water, 4 times daily)
Study: 12233808
Drug: Ginger syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger syrup
Study: 7778813
Drug: Cephalosporine 1
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporine 1 (5-day administration)
Study: 7778813
Drug: Cephalosporine 2
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporine 2 (2-day treatment)
Study: 7778813
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics for clean, planned surgery (grade II)
Study: 2531557
Drug: 10 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms.kg‐1 sufentanil as an induction dose plus 0.15 microgram.kg‐1.min‐1 continuous infusion
Study: 2531557
Drug: 10 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms.kg‐1 sufentanil as an induction dose plus 0.3 microgram.kg‐1.min‐1 continuous infusion
Study: 21575503
Drug: L‐OHP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐OHP + CAP (oxaliplatin plus capecitabine)
Study: 15119989
Drug: GAL 24
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GAL 24 mg (12 mg BID)
Study: 15119989
Drug: GAL 16
Normalized name: QUATERNIUM-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL 16 mg (8 mg BID)
Study: 9773664
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate 6 mg/kg/day for 10 days
Study: 8064733
Drug: S-adenosylmethionine (SAM)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAM) intravenous boluses of 400 mg for 5 days, followed by oral tablets, 200 mg thrice daily for 23 days
Study: 3069750
Drug: Fenticonazole vaginal
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole vaginal ovules 200 mg
Study: 3069750
Drug: Fenticonazole vaginal
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole vaginal ovules 600 mg
Study: 3069750
Drug: Fenticonazole vaginal
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole vaginal ovules 1,000 mg
Study: 29078966
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) on PC6 acupuncture point
Study: 18275361
Drug: Compressed air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressed air massage (15-20 min daily at 1 bar pressure, 5 days a week)
Study: 11916198
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (6 MIU interferon-alpha-2a daily for 4 weeks followed by 3 MIU thrice weekly for 22 weeks)
Study: 11916198
Drug: Standard interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interferon therapy (3 MIU interferon-alpha-2a thrice weekly for 26 weeks)
Study: 11916198
Drug: Standard interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interferon therapy
Study: 10091835
Drug: Meal rich
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal rich in used cooking fat (fat 64.4 g)
Study: 10091835
Drug: Meal rich
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal rich in unused cooking fat (fat 64.4 g)
Study: 10091835
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat meal (fat 18.4 g)
Study: 1398465
Drug: GH-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-releasing hormone (GHRH)
Study: 7208542
Drug: Iron poly
Normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron poly (sorbitol‐gluconic acid) complex (IPSG) 250 mg elemental iron per week for 8 weeks